Propanc Biopharma Raises Up To $100 Million Through Private Placement To Boost Research & Development And Drive Digital Asset Expansion

Propanc Biopharma, Inc., a biopharmaceutical company focused on developing innovative treatments for patients with recurrent and metastatic cancer, has announced that it has entered into a securities purchase agreement with Hexstone Capital LLC, a family office investor with a strong portfolio across the Digital Asset Treasury (DAT) space. Hexstone has invested in multiple digital assets, including BTC, ETH, SOL, DOGE, ATH, OG, and INJ.

Under the terms of the agreement, Hexstone will provide up to $100 million in funding through a private placement of convertible preferred stock. The proceeds will be used to strengthen Propanc’s digital asset acquisition strategy and accelerate its research and development initiatives, particularly in advancing PRP (proenzyme therapy) into its first-in-human clinical trial, expected to commence in the second half of 2026.

At the initial closing, Propanc received an investment of $1 million through the issuance of 100 shares of newly designated Series C Convertible Preferred Stock, each with a par value of $0.01 and an initial stated value of $10,000. This marks the beginning of what the company describes as a transformative funding partnership to support both its financial and clinical growth.

James Nathanielsz, Chief Executive Officer of Propanc Biopharma, highlighted the strategic importance of this agreement, stating, “We are entering a transformative phase for the company as we work to build our digital asset base and strengthen our balance sheet. This funding will enable us to accelerate our unique proenzyme technology toward clinical development and beyond. 

Our business model is designed to revolutionize how we fund and grow our intellectual property portfolio, fast-track our R&D activities, and expand our development programs. Ultimately, our goal is to target not only patients suffering from metastatic cancers derived from solid tumors but also multiple chronic diseases based on the mechanism of action of proenzyme therapy. This is our vision for the future of Propanc, and we look forward to updating stakeholders as we make progress.”

In addition to the initial investment, Propanc will issue 9,900 warrants to Hexstone Capital. Each warrant entitles the holder to purchase one share of preferred stock at $10,000 per share, representing a total potential funding value of $99 million. These warrants are exercisable immediately and remain valid for 12 months.

The agreement also allows the company to exercise a call option—subject to certain equity conditions and beneficial ownership limits—of up to 500 warrants per calendar month at a nominal price of $0.01 per warrant. This mechanism enables Propanc to access up to $5 million in preferred stock funding per month, adjusted for any warrants already exercised during that period.

This strategic partnership with Hexstone Capital provides Propanc with the financial flexibility to continue developing its proenzyme therapy platform (PRP), an emerging approach aimed at addressing the underlying mechanisms of cancer metastasis. By combining biopharmaceutical innovation with a forward-looking digital asset investment strategy, Propanc aims to build a sustainable growth model that supports both its R&D pipeline and long-term shareholder value.